TY - JOUR
T1 - F-18-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
AU - Duch, Joan
AU - Fuster, David
AU - Munoz, Montserrat
AU - Luis Fernandez, Pedro
AU - Paredes, Pilar
AU - Fontanillas, Montserrat
AU - Guzman, Flavia
AU - Rubi, Sebastia
AU - Juan Lomena, Francisco
AU - Pons, Francesca
PY - 2009/10
Y1 - 2009/10
N2 - Purpose The aim of this study was to prospectively evaluate F-18-FDG PET/CT in predicting response to neoadjuvant chemotherapy in large primary breast cancer.Methods Fifty consecutive patients underwent PET/CT at baseline and after the second cycle. Baseline MRI was performed to establish tumour size. All findings were confirmed by histopathological analysis. Changes in maximum standardized uptake value (SUVmax) between baseline study and after two cycles of neoadjuvant chemotherapy (epirubicin + cyclophosphamide + taxanes) were compared using response evaluation criteria in solid tumours (RECIST) criteria and the Miller and Payne (M&P) scale.Results The mean tumour size was 4.3 +/- 1.4 cm. Forty patients were considered responders and ten as non-responders. SUVmax changes in patients with good prognosis (M&P grades 4-5) were higher than in patients with bad prognosis (M& P grades 1-3) (p= 0.025). SUVmax changes between responders and non-responders following RECIST criteria were also statistically significant (p= 0.0028). A cut-off Delta SUV value of 40% differentiates both groups, with a sensitivity of 77% and a specificity of 80%.Conclusion F-18-FDG PET/CT can predict response to neoadjuvant chemotherapy at an early stage.
AB - Purpose The aim of this study was to prospectively evaluate F-18-FDG PET/CT in predicting response to neoadjuvant chemotherapy in large primary breast cancer.Methods Fifty consecutive patients underwent PET/CT at baseline and after the second cycle. Baseline MRI was performed to establish tumour size. All findings were confirmed by histopathological analysis. Changes in maximum standardized uptake value (SUVmax) between baseline study and after two cycles of neoadjuvant chemotherapy (epirubicin + cyclophosphamide + taxanes) were compared using response evaluation criteria in solid tumours (RECIST) criteria and the Miller and Payne (M&P) scale.Results The mean tumour size was 4.3 +/- 1.4 cm. Forty patients were considered responders and ten as non-responders. SUVmax changes in patients with good prognosis (M&P grades 4-5) were higher than in patients with bad prognosis (M& P grades 1-3) (p= 0.025). SUVmax changes between responders and non-responders following RECIST criteria were also statistically significant (p= 0.0028). A cut-off Delta SUV value of 40% differentiates both groups, with a sensitivity of 77% and a specificity of 80%.Conclusion F-18-FDG PET/CT can predict response to neoadjuvant chemotherapy at an early stage.
KW - Breast cancer
KW - PET/CT
KW - Early prediction response
KW - Neoadjuvant chemotherapy
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - CELL LUNG-CANCER
KW - PATHOLOGICAL RESPONSE
KW - FDG-PET
KW - PREOPERATIVE CHEMOTHERAPY
KW - INDUCTION CHEMOTHERAPY
KW - TUMOR RESPONSE
KW - CARCINOMA
KW - FLUORODEOXYGLUCOSE
KW - THERAPY
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-70350539566&partnerID=MN8TOARS
U2 - 10.1007/s00259-009-1116-y
DO - 10.1007/s00259-009-1116-y
M3 - Article
SN - 1619-7070
VL - 36
SP - 1551
EP - 1557
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 10
ER -
